Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis

Summary

This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.

Timeline

Start

2025-11-27

Primary completion

2027-07

Completion

2027-09

Drugs

Indications